Theriva Biologics announced a positive review from the Data and Safety Monitoring Committee for its SYN-004 clinical trial, allowing it to proceed to the next cohort, while seeking additional funding for the study.
AI Assistant
THERIVA BIOLOGICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.